{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:48:46Z","timestamp":1791611326166,"version":"4.3.4"},"reference-count":10,"publisher":"Japanese Urological Association","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn. j. urol"],"published-print":{"date-parts":[[2026,4,20]]},"DOI":"10.5980\/jpnjurol.117.48","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:13:25Z","timestamp":1791497605000},"page":"48-51","source":"Crossref","is-referenced-by-count":0,"title":["A CASE OF AUTOIMMUNE HEMOLYTIC ANEMIA FOLLOWING PEMBROLIZUMAB PLUS LENVATINIB THERAPY FOR METASTATIC RENAL CELL CARCINOMA","\u8ee2\u79fb\u6027\u814e\u764c\u306b\u5bfe\u3057\u3066\u30da\u30e0\u30d6\u30ed\u30ea\u30ba\u30de\u30d6\uff0b\u30ec\u30f3\u30d0\u30c1\u30cb\u30d6\u7642\u6cd5\u5f8c\u306b\u81ea\u5df1\u514d\u75ab\u6027\u6eb6\u8840\u6027\u8ca7\u8840\u3092\u767a\u75c7\u3057\u305f\u4e00\u4f8b"],"prefix":"10.5980","volume":"117","author":[{"given":"Soichiro","family":"Murayama","sequence":"first","affiliation":[{"name":"Hakodate Goryokaku Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Matsuki","sequence":"additional","affiliation":[{"name":"Hakodate Goryokaku Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Hakodate Goryokaku Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Hakodate Goryokaku Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Hakodate Goryokaku Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4001","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Gr\u00fcnwald V, Hutson TE, Kopyltsov E, M\u00e9ndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D and Choueiri TK; CLEAR Trial Investigators: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med, 2021.","DOI":"10.1056\/NEJMoa2035716"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Leaf RK, Ferreri C, Rangachari D, Mier J, Witteles W, Ansstas G, Anagnostou T, Zubiri L, Piotrowska Z, Oo TH, Iberri D, Yarchoan M, Salama AKS, Johnson DB, Leavitt AD, Rahma OE, Reynolds KL and Leaf DE: Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. Am J Hematol, 2019.","DOI":"10.1002\/ajh.25448"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Souli\u00e8res D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB and Powles T; KEYNOTE-426 Investigators: Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med, 2019.","DOI":"10.1056\/NEJMoa1816714"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Michot JM, Lazarovici J, Tieu A, Champiat S, Voisin AL, Ebbo M, Godeau B, Michel M, Ribrag V and Lambotte O: Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage? Eur J Cancer, 2019.","DOI":"10.1016\/j.ejca.2019.07.014"},{"key":"5","unstructured":"5) \u5f35\u66ff \u79c0\u90ce\u7de8: \u81ea\u5df1\u514d\u75ab\u6027\u6eb6\u8840\u6027\u8ca7\u8840\u8a3a\u7642\u306e\u53c2\u7167\u30ac\u30a4\u30c9, \u4ee4\u548c4\u5e74\u5ea6\u6539\u8a02\u7248."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Sa\u00efag P, Madonna E, Maerevoet M, Bout JC, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albig\u00e8s L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin AL, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M and Lambotte O: Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol, 2019.","DOI":"10.1016\/S2352-3026(18)30175-3"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) G\u00fczel HG and K\u0131vrak Salim D: Tyrosine kinase inhibitor-induced immune hemolytic anemia; three different drugs in three separate cases. J Oncol Pharm Pract, 2024.","DOI":"10.1177\/10781552231202530"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Tanios GE, Doley PB and Munker R: Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review. Eur J Haematol, 2019.","DOI":"10.1111\/ejh.13187"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Pla\u00e7ais M, Laparra A, Maria ATJ, Kramkimel N, Perret A, Manson G, Comont T, Coutte L, Nardin C, Ouali K, Danlos FX, No\u00ebl N, Messayke S, Michel M, Lambotte O and Michot JM: Drug-induced autoimmune hemolytic anemias related to immune checkpoint inhibitors, therapeutic management, and outcome. Am J Hematol, 2024.","DOI":"10.1002\/ajh.27339"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Gnanapandithan K, Kharel P, Cruz Carreras MT, Gonz\u00e1lez Landr\u00f3n F, L\u00f3pez N, Padr\u00f3n Alc\u00e1ntara L, Markides DM, Burk KJ and Chaftari P: Hematologic immune-related adverse events from immune checkpoint inhibitors: a systematic review of case-reports and case-series. Blood, 2019.","DOI":"10.1182\/blood-2019-132203"}],"container-title":["The Japanese Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/117\/2\/117_48\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:55:30Z","timestamp":1791608130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/117\/2\/117_48\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5980\/jpnjurol.117.48","relation":{},"ISSN":["0021-5287","1884-7110"],"issn-type":[{"value":"0021-5287","type":"print"},{"value":"1884-7110","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]}}}